Fraunhofer is hosting this... --> 3/22-3/25
Fraunhofer is... per Ibio Website -->
Fraunhofer USA Center for Molecular Biotechnology (FCMB)
iBio owns technology created by the not-for-profit research organization
FCMB operates cGMP pilot plant based on the iBioLaunchTM Platform
--- the PR below... ---
NEWARK, Del.--(BUSINESS WIRE)--More than 100 scientists, business leaders and regulatory agency representatives from around the world will convene at the Hotel DuPont in Wilmington, DE from March 22–25, 2015 for the 10th anniversary of the New Technologies, New Vaccines conference, to share advancements in the fight against deadly diseases and prevention of potential epidemics including chikungunya, dengue, Ebola, influenza and HIV.
“With the growing global demand for vaccines and other biologics, the need for new high-performance technologies for vaccine identification, design, development and manufacturing is critical”
The 3-day conference brings together leaders from business and industry, academia and government to discuss latest developments in therapeutic treatments and life-saving vaccines. The event is organized by Fraunhofer USA Center for Molecular Biotechnology (CMB), located at the Delaware Technology Park in Newark, Delaware, in cooperation with the International Association for Biological Standardization (IABS), headquartered in Geneva, Switzerland.
Initiated in 2006, the conference explores how new technologies are enhancing our ability to identify and design new vaccine candidates, develop safe and effective vaccine formulations using improved drug-enhancing agents and delivery mechanisms, and providing innovative manufacturing platforms to produce vaccines more safely, quickly and economically than traditional approaches.
“With the growing global demand for vaccines and other biologics, the need for new high-performance technologies for vaccine identification, design, development and manufacturing is critical,” explained Fraunhofer USA CMB Executive Director Dr. Vidadi Yusibov.
One such bio-manufacturing platform is plants - highlighted in recent efforts by the Biomedical Advanced Research and Development Authority (BARDA) for manufacturing the Ebola monoclonal antibody-based therapeutic, ZMAPP.
“During the conference, we will share new knowledge and facilitate discussions and potential collaborations among representatives from academic research, government and industry fostering additional discoveries and development of new tools for effective prevention of global epidemic threats,” Yusibov added.
Featured keynote speaker Kathryn Zoon, Ph.D., Director of the Division of Intramural Research (DIR) at National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), will present on the stages of vaccine development and current challenges. Dr. Zoon provides overall executive direction and scientific leadership for the division’s basic and clinical research activities, which cover a wide range of biomedical disciplines related to infectious diseases, immunology and allergy.
Additional topics planned over the 3-day conference include next generation products for prevention and treatment of auto-immune diseases such as cancer, HSV and HIV, advancements in protein expression and production methods and regulatory considerations for new technologies.
Conference registration and additional information is available online at www.ntnv.org.
